J&J Medical Connect
SYMTUZA®

(darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)
Medical Information

Open Bottle Stability of SYMTUZA Tablets

Last Updated: 07/23/2026

Summary

  • An in-use stability study of SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide 800/150/200/10 mg) oral film-coated tablets in 120 mL high density polyethylene (HDPE) bottles was performed to simulate the daily use of the medication by the patient.1
  • The tablets were stored in an HDPE bottle with desiccant, at 25°C/60% relative humidity (RH) and 30°C/75% RH, and the bottle was opened once daily for 6 weeks. The product remained stable for the 6-week study period. This study was not conducted to assess open bottle stability for longer periods of time.1

Literature search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® databases (and/or other resources, including internal/external databases) conducted on 03 September 2025. No relevant literature pertaining to this topic was identified.

References

Show
1 Data on File. In-Use Stability Report for 800/150/200/10 mg Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Coated Tablets. Janssen Research & Development, LLC. TV-TEC-155986; 2018.  

Would you like to clear and leave your conversation? Message history will be lost.